Rebastinib (DCC-2036)
Rebastinib (DCC-2036)
ChemLeader
Catalog No:
CAS No.:
MDLNo:
Formula:
MW:
Size
5 mg 10 mg 25 mg
Product Availability
3-5days
Price
$155.00
Member price
Product Availability
3-5days
Price
$250.00
Member price
Product Availability
3-5days
Price
$450.00
Member price
Quantity
- +
Product Overview
Product Name Rebastinib (DCC-2036)
CAS1020172-07-9
FormulaC30H28FN7O3
MW553.59
AppearanceWhite to off-white powder
Storage conditionDry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).
Security information
Product details

Rebastinib (formerly also known as DCC-2036), a novel, potent and orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity, is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50s of 0.8 nM and 4 nM. It also inhibits other kinases such as SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and has low activity towards c-Kit. DCC-2036 inhibits ABL1 through forcing the kinase domains into inhibitor-bound, inactive Type II conformations. In cellular assay, DCC-2036 inhibits the proliferation of Ba/F3 and K562 cells with IC50 values of 5.4nM and 5.5nM, respectively.

Related literature
Related
Sorry, no related items
History
Tesevatinib (Synonyms: XL-647; EXEL-7647; KD-019)
3-(1-(((3r,5r,7r)-adamantan-1-yl)methyl)-5-methyl-1H-pyrazol-4-yl)-6-(8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)picolinic acid
LY2109761
(E/Z)-4-Hydroxytamoxifen | Afimoxifene | cis/trans-4-Hydroxytamoxifen
Cycloastragenol | Cyclosiversigenin | Astramembrangenin | Cyclosieversigenin
Anti-Human CD3xCD20 (Synonyms: Glofitamab; RO7082859; CD20-TCB ,RG-6026;CD3e, CD3 epsilon;membrane-spanning 4-domains subfamily A member 1, CD20,MS4A1)
Golimumab (Synonyms: CNTO-148; Anti-TNFSF2 / TNFa)
Girentuximab (Anti-CA9 / Carbonic anhydrase 9)
4-Vinylphenol (4-Hydroxystyrene); p-Vinylphenol
Rebastinib (DCC-2036)